Cumberland Swings To $77.8 Million Profit With An $81.1 Million Business-Sale Gain
The retained business lost $1.1 million as Cumberland turned its resources toward rare-disease drug development.
Cumberland Pharmaceuticals, which is developing medicines for rare diseases after selling its commercial drug business, swung to an unaudited third-quarter profit of $77.8 million from a $1.9 million loss a year earlier. Results furnished with Tuesday's SEC filing included an $81.1 million business-sale gain, while the operations it kept lost $1.1 million.
The Profit Behind The Pivot
Diluted earnings were $5.07 a share, compared with a $0.13 loss a year earlier. The loss from continuing operations narrowed from $2.7 million, even as quarterly research spending increased to $841,162 from $646,473.
Cumberland's cash reached $80.6 million at September 30, compared with $11.4 million at the end of 2025. During the first nine months of 2026, it paid $22.5 million in cash dividends, versus none in the corresponding 2025 period, and repaid $5.2 million on its credit line.
Continuing operations used $1.1 million in operating cash during those nine months, compared with $2.5 million a year earlier. Quarterly interest income rose to $822,886 from $131,583; general and administrative spending fell to $2.2 million from $2.4 million.
From Drug Sales To Drug Development
Apotex Health paid Cumberland $100 million at the July 1 closing for its commercial brands and organization, which joined Apotex's U.S. branded business. The third quarter was Cumberland's first full operating period after that sale.
The company previously bought, developed and sold branded prescription medicines focused on hospital acute care, gastroenterology and oncology. Its retained pipeline is led by ifetroban, also being studied in idiopathic pulmonary fibrosis and cancer metastasis.
“Our team and resources are now dedicated to developing new medicines for unmet medical needs,” Cumberland CEO A.J. Kazimi said.
Ifetroban's Path To The FDA
Cumberland plans to seek FDA approval for ifetroban to treat heart disease associated with Duchenne muscular dystrophy. The agency granted a rolling review, allowing completed portions of the application to be reviewed before Cumberland submits the full package.
The company said its mid-stage trial found a 5.4-percentage-point improvement in a measure of the heart's pumping ability in the high-dose group relative to a control group combining placebo patients and matched natural-history patients. It plans to include long-term extension data, manufacturing information and safety findings from more than 1,400 subjects across approximately 30 studies in the application.
That development timetable has changed before. In August, Cumberland said long-term safety and efficacy data were not available for a presentation it had planned that month.
Separately, results announced October 23 supported safety and tolerability in patients with systemic sclerosis. Cumberland plans to send the study report to the FDA and conduct additional biomarker and cardiac-imaging work to help decide whether to continue developing ifetroban for that disease.
Cumberland plans to pursue the Duchenne application without additional trials, but cautioned that the FDA could require more studies and data. Rolling review does not guarantee a shorter review or approval.
Sources
- 8-K Filing — CUMBERLAND PHARMACEUTICALS INC (CPIX) — SEC EDGAR
- Exhibit a2026q3-ex991er.htm — CUMBERLAND PHARMACEUTICALS INC 8-K exhibit — SEC EDGAR
- CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE — prnewswire.com
- 8-K filed 2026-10-23 — CUMBERLAND PHARMACEUTICALS INC (earlier disclosure) — SEC EDGAR
- 8-K filed 2026-08-28 — CUMBERLAND PHARMACEUTICALS INC (earlier disclosure) — SEC EDGAR